ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average of $5.03

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.03 and traded as high as $5.20. ImmuCell shares last traded at $5.15, with a volume of 11,974 shares.

ImmuCell Stock Performance

The firm’s 50-day moving average price is $5.17 and its 200 day moving average price is $5.03. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.87 and a current ratio of 2.73. The company has a market cap of $39.92 million, a price-to-earnings ratio of -6.87 and a beta of 0.59.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.15) earnings per share for the quarter. ImmuCell had a negative return on equity of 21.79% and a negative net margin of 33.05%. The firm had revenue of $5.10 million for the quarter.

Institutional Trading of ImmuCell

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in ImmuCell by 22.2% during the first quarter. Vanguard Group Inc. now owns 204,325 shares of the biotechnology company’s stock worth $1,972,000 after buying an additional 37,081 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ImmuCell by 7.4% in the third quarter. Dimensional Fund Advisors LP now owns 22,579 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 1,563 shares in the last quarter. Morgan Stanley grew its stake in shares of ImmuCell by 3.8% in the fourth quarter. Morgan Stanley now owns 76,874 shares of the biotechnology company’s stock valued at $469,000 after acquiring an additional 2,800 shares in the last quarter. Cresset Asset Management LLC lifted its position in ImmuCell by 4.2% during the first quarter. Cresset Asset Management LLC now owns 100,506 shares of the biotechnology company’s stock worth $518,000 after purchasing an additional 4,080 shares during the period. Finally, Geode Capital Management LLC lifted its position in ImmuCell by 20.1% during the second quarter. Geode Capital Management LLC now owns 45,727 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 7,645 shares during the period. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.